TCG Opportunity III GP, LLC is Director & 10% Owner at NGM BIOPHARMACEUTICALS INC (NGM). They have made 8 open-market trades across 3 companies since 2022, most recently 2026-02-25.
CIK 0001932445
7 open-market purchases totalling $1.0M since 2022, against 1 sale. Across 7 scored buys the stock is down 9.9% at ninety days, and 11.5 points behind the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| SRZN | 996,502 | $23.4M |
| TNYA | 1,649,281 | $613K |
| NGM | 1,000 | $2K |
| Total | $24.0M |
Shares reported on the most recent Form 4, priced at the 2026-02-26 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 43% | 29% | 29% |
| Avg Move | -1.3% | -4.9% | -9.9% |
| Alpha | -1.4% | -4.7% | -11.5% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TNYA | SELL | 2026-02-24 | 2026-02-26 | $0.57 | $2.4M | +47.0% | +2.2% | +31.3% |
| SRZN | BUY | 2026-01-13 | 2026-01-15 | $19.86 | $357K | +5.7% | +19.6% | +56.1% |
| NGM | BUY | 2023-01-30 | 2023-02-01 | $5.00 | $38K | -9.6% | -20.7% | -32.2% |
| NGM | BUY | 2023-01-20 | 2023-01-23 | $5.00 | $3K | -0.9% | -12.6% | -25.9% |
| NGM | BUY | 2023-01-12 | 2023-01-17 | $4.95 | $27K | -3.6% | -11.9% | -25.8% |
| NGM | BUY | 2022-12-12 | 2022-12-14 | $4.98 | $1K | -16.1% | -0.6% | -26.5% |
| NGM | BUY | 2022-11-22 | 2022-11-23 | $5.00 | $22K | +1.5% | -11.7% | -18.3% |
| NGM | BUY | 2022-10-25 | 2022-10-27 | $4.81 | $595K | +14.1% | +3.4% | +3.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.